| Literature DB >> 30656171 |
Omid Hesami1, Mahsa Haghighatzadeh1, Behnam Safarpour Lima1, Naghmeh Emadi2, Shahin Salehi3.
Abstract
Carpal tunnel syndrome (CTS) is one of the reasons for labor abandonment due to inability and pain. The aim of this study was to evaluate the effectiveness of gabapentin and exercise training in the treatment of CTS and compare their effects. This single-blind clinical trial was conducted on patients referred to the Imam Hossein hospital's electrodiagnostic (EDX) unit. The patients randomly assigned into four groups: using nocturnal splint as an approved treatment in the control group; taking 300-mg gabapentin per night and using nocturnal splint; nerve and tendon gliding exercises and using nocturnal splint; and taking 300-mg gabapentin per night, performing same exercise as group 3 and using nocturnal splint. At baseline, four indicators were assessed in all patients, including the Boston carpal tunnel questionnaire, visual analogue scale (VAS), pinch and grip strength of the affected hand. One month after the beginning of intervention, participants were reassessed and compared for each of the four indicators. Using nocturnal splint along with exercise and gabapentin significantly improved VAS, pinch and grip strength in moderate CTS compared to control group that only used nocturnal splint. However in mild CTS, grip strength was not significantly higher compared to control group (P=0.048). Results of this study showed that use of splint alone in mild CTS is an appropriate and sufficient treatment; however, in moderate CTS, receiving gabapentin along with exercise and splinting showed better treatment results compared to splinting alone.Entities:
Keywords: Boston carpal tunnel questionnaire; Carpal tunnel syndrome; Exercise; Gabapentin; Grip and pinch strength; Visual analogue scale
Year: 2018 PMID: 30656171 PMCID: PMC6323333 DOI: 10.12965/jer.1836420.210
Source DB: PubMed Journal: J Exerc Rehabil ISSN: 2288-176X
Fig. 1Flow chart of trial and number of patients. From 230 patients of eligibility, 98 patients were randomized and 82 patients completed the course of intervention.
Demographic data and preintervention status of patients in different groups
| Characteristic | Exercise | Gabapentin | Exercise+ gabapentin | Control | |
|---|---|---|---|---|---|
| Age (yr) | 54.17±9.99 | 41.04±8.46 | 47.13±9.14 | 48.30±9.96 | <0.001 |
|
| |||||
| Gender | 0.006 | ||||
| Male | 6 (26.1) | 0 (0) | 0 (0) | 4 (20) | |
| Female | 17 (73.9) | 23 (100) | 16 (100) | 16 (80) | |
|
| |||||
| BMI | 0.04 | ||||
| Normal | 2 (8.7) | 0 (0) | 5 (31.3) | 3 (15) | |
| Overweight | 9 (39.1) | 12 (52.2) | 9 (56.3) | 9 (45) | |
| Obesity grade I | 7 (30.4) | 10 (43.5) | 2 (12.5) | 7 (35) | |
| Obesity grade II | 5 (21.7) | 1 (4.3) | 0 (0) | 1 (5) | |
|
| |||||
| Severity | 0.246 | ||||
| Mild | 13 (56.5) | 19 (82.6) | 11 (68.8) | 12 (60) | 0.035 |
| Moderate | 10 (43.5) | 4 (17.4) | 5 (31.3) | 8 (40) | 0.068 |
|
| |||||
| Boston.SSS | 20.52±10.05 | 22.43±7.75 | 27.31±7.60 | 25.60±4.25 | <0.001 |
|
| |||||
| Boston.FSS | 21.52±10.56 | 18.30±9.49 | 25.38±8.34 | 19.20±3.43 | <0.001 |
|
| |||||
| Grip strength | 23.28±7.60 | 20.04±6.91 | 14.06±6.45 | 15.65±4.78 | 0.422 |
|
| |||||
| Pinch strength | 6.76±1.48 | 5.80±2.09 | 3.75±1.92 | 5.85±1.51 | <0.001 |
|
| |||||
| VAS | 6.30±2.58 | 6.74±2.78 | 7.19±2.14 | 6.00±0.97 | 0.422 |
Values are presented as mean±standard deviation or number (%).
BMI, body mass index; Boston, Boston carpal tunnel questionnaire; SSS, symptom severity scale; FSS, functional status scale; VAS, visual analogue scale.
BMI (kg/m2): normal, 18.5–24.9; overweight, 25.0–29.9; obesity grade I, 30.0–34.9; obesity grade II, 35.0–39.9.
Postintervention mean for mild and moderate group and the whole sample
| Outcome | Mild | Moderate | Total | |||
|---|---|---|---|---|---|---|
|
|
|
| ||||
| Mean±SD | Mean±SD | Mean±SD | ||||
| Boston.SSS | 0.26 | 0.449 | 0.104 | |||
| Exercise+gabapentin | 19.91±8.5 | 15.40±7.99 | 18.50±8.36 | |||
| Exercise | 15.31±9.48 | 18.90±10.46 | 16.87±9.85 | |||
| Gabapentin | 20.42±5.33 | 16.00±3.65 | 19.65±5.29 | |||
| Control | 20.92±3.15 | 21.88±5.25 | 21.30±4.01 | |||
|
| ||||||
| Boston.FSS | 0.701 | 0.023 | 0.895 | |||
| Exercise+gabapentin | 24.45±6.23 | 17.20±7.16a) | 22.19±7.19 | |||
| Exercise | 16.85±11.55 | 21.90±10.00b) | 19.04±10.97 | |||
| Gabapentin | 17.84±8.98 | 16.75±7.18 | 17.65±8.56 | |||
| Control | 16.75±3.55 | 17.25±2.71 | 16.95±3.17 | |||
|
| ||||||
| Grip strength | 0.048 | 0.021 | 0.023 | |||
| Exercise+gabapentin | 19.86±8.35a) | 16.40±9.40a) | 18.78±8.53a) | |||
| Exercise | 25.69±4.03 | 22.75±7.80 | 24.41±6.00 | |||
| Gabapentin | 20.16±5.89 | 22.50±1.73 | 20.57±5.44 | |||
| Control | 16.08±3.87b) | 18.38±6.35b) | 17.00±4.98 | |||
|
| ||||||
| Pinch strength | 0.619 | 0.001 | 0.19 | |||
| Exercise+gabapentin | 5.64±2.09 | 6.10±2.38a) | 5.78±2.11 | |||
| Exercise | 7.42±1.22 | 7.10±1.93b) | 7.28±1.54 | |||
| Gabapentin | 6.40±1.62 | 7.75±1.26b) | 6.63±1.63 | |||
| Control | 6.17±1.15 | 7.13±2.23b) | 6.55±1.69 | |||
|
| ||||||
| VAS | 0.778 | 0.015 | 0.187 | |||
| Exercise+gabapentin | 4.30±2.06 | 4.20±2.28a) | 4.27±2.05 | |||
| Exercise | 4.15±2.23 | 4.70±2.63b) | 4.39±2.37 | |||
| Gabapentin | 5.11±2.18 | 2.00±2.83 | 4.57±2.54 | |||
| Control | 4.75±1.06 | 5.00±1.07b) | 4.85±1.04 | |||
SD, standard deviation; Boston, Boston carpal tunnel questionnaire; SSS, symptom severity scale; FSS, functional status scale; VAS, visual analogue scale.
Analysis of covariance - adjusted for baseline measurements, age, gender, body mass index (BMI).
Analysis of covariance - adjusted for baseline measurements, age, gender, BMI, severity of the disease.
Different letters (a,b) indicate significant differences (group marked by letter a)shows significantly better performance).